Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

Now Viewing

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.

Pipe delves into the real-world evidence surrounding factor replacement therapy and emicizumab in treating hemophilia A. With a robust clinical trial program involving hundreds of patients, the discussion extends to over 2300 individuals in real-world settings, shedding light on adherence, efficacy, and outcomes. The data suggests that patients on emicizumab prophylaxis consistently maintain low annualized bleed rates, often ranging from zero to 2, with a significant proportion achieving zero treated bleeds annually. Pipe explores switching studies, acknowledging mixed results, especially in regions with varying prophylaxis approaches. While annualized bleed rates may not always show a clear differentiator, patient preferences, quality of life measures, and activity levels strongly favor emicizumab due to its regimen ease, subcutaneous delivery, and steady-state levels. The interview also touches on cost considerations, noting that in the US, emicizumab's pricing might result in higher annualized costs compared to standard half-life agents. The comprehensive analysis underscores the importance of real-world evidence in understanding the practical implications and patient-centric benefits of these evolving hemophilia A therapies.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.